Literature DB >> 20189690

[Policies encouraging price competition in the generic drug market: Lessons from the European experience].

Jaume Puig-Junoy1.   

Abstract

OBJECTIVES: To describe alternative policies aimed at encouraging price competition in generic drug markets in countries with strict price regulation, and to present some case studies drawn from the European experience.
METHODS: Systematic literature review of articles and technical reports published after 1999.
RESULTS: The shortcomings in consumer price competition observed in some European generic markets, including Spain, may be reduced through three types of public reimbursement or financing reforms: policies aimed at improving the design of current maximum reimbursement level policies; policies aimed at monitoring competitive prices in order to reimburse real acquisition cost to pharmacies; and, more radical and market-oriented policies such as competitive tendering of public drug purchases. The experience of recent reforms adopted in Germany, Belgium, Holland, Norway, and Sweden offers a useful guide for highly price-regulated European countries, such as Spain, currently characterized by limited consumer price competition and the high discounts offered to pharmacy purchases.
CONCLUSIONS: Direct price regulation and/or the generic reference pricing systems used to reduce generic drug prices in many European countries can be successfully reformed by adopting measures more closely aimed at encouraging consumer price competition in generic drug markets. Copyright 2009 SESPAS. Published by Elsevier Espana. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 20189690     DOI: 10.1016/j.gaceta.2009.12.003

Source DB:  PubMed          Journal:  Gac Sanit        ISSN: 0213-9111            Impact factor:   2.139


  6 in total

1.  Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain.

Authors:  Antoni Sicras-Mainar; Javier Rejas-Gutiérrez; Ruth Navarro-Artieda
Journal:  Clinicoecon Outcomes Res       Date:  2015-06-04

Review 2.  Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

Authors:  Brian Godman; William Shrank; Bjorn Wettermark; Morten Andersen; Iain Bishop; Thomas Burkhardt; Kristina Garuolienè; Marija Kalaba; Ott Laius; Roberta Joppi; Catherine Sermet; Ulrich Schwabe; Inês Teixeira; F Cankat Tulunay; Kamila Wendykowska; Corinne Zara; Lars L Gustafsson
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-05

3.  Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis.

Authors:  A Sicras-Mainar; L Sánchez-Álvarez; R Navarro-Artieda; J Darbà
Journal:  Lipids Health Dis       Date:  2018-12-06       Impact factor: 3.876

Review 4.  Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.

Authors:  Angela Acosta; Agustín Ciapponi; Morten Aaserud; Valeria Vietto; Astrid Austvoll-Dahlgren; Jan Peter Kösters; Claudia Vacca; Manuel Machado; Diana Hazbeydy Diaz Ayala; Andrew D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2014-10-16

5.  Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity.

Authors:  Antoni Sicras-Mainar; Javier Rejas-Gutiérrez; María Pérez-Páramo; Ruth Navarro-Artieda
Journal:  J Eval Clin Pract       Date:  2016-09-27       Impact factor: 2.431

6.  Analysis of the Korean generic medicine market: Factors affecting the market share of generic medicines.

Authors:  Dong-Sook Kim; Jihye Shin; Jusun Chung
Journal:  Clin Transl Sci       Date:  2021-09-29       Impact factor: 4.689

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.